Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Achieve Life Sciences (ACHV) Shares Issued (2017 - 2026)

Achieve Life Sciences (ACHV) has disclosed Shares Issued for 15 consecutive years, with $21000.0 as the latest value for Q1 2026.

Quarterly Shares Issued changed N/A to $21000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2026, changed N/A year-over-year, with the annual reading at $1.4 million for FY2025, 678.09% up from the prior year.
Shares Issued for Q1 2026 was $21000.0 at Achieve Life Sciences, down from $1.3 million in the prior quarter.
The five-year high for Shares Issued was $56.1 million in Q1 2024, with the low at -$55.9 million in Q3 2024.
Average Shares Issued over 5 years is $166818.2, with a median of $77000.0 recorded in 2023.
The sharpest move saw Shares Issued crashed 10100.0% in 2022, then skyrocketed 72770.13% in 2024.
Achieve Life Sciences' Shares Issued stood at -$102000.0 in 2022, then surged by 247.06% to $150000.0 in 2023, then crashed by 37362.0% to -$55.9 million in 2024, then soared by 102.26% to $1.3 million in 2025, then tumbled by 98.34% to $21000.0 in 2026.
Per Business Quant, the three most recent readings for ACHV's Shares Issued are $21000.0 (Q1 2026), $1.3 million (Q4 2025), and $120000.0 (Q3 2025).